(USD) | Jun 2023 | Q/Q |
---|---|---|
Revenue | 1MM | -45% |
Operating Income | -72.6MM | +18% |
Operating Expenses | 73.6MM | - |
Net Income | -66.9MM | +11% |
R&D | 57.9MM | +14% |
G&A | 13.1MM | +15% |
Amortization | 433K | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody. “Initiation of th
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV
Zigakibart Treatment Results in Rapid and Sustained Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Zigakibart produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy Zigakibart Treatment Results in Rapid and Sustained Reductions in IgA and Gd-IgA1 in Patients with IgA Nephropathy Zigakibart produced rapid and sustained reductions in IgA and Gd-IgA1, the pathogenic variant of IgA nephropathy Zigakibart Treatment Results in Clinically M
Illumina CEO Francis deSouza has stepped down after a lengthy proxy battle with activist investor Carl Icahn. Yahoo Finance health care reporter Anjalee Khemlani breaks down the timeline of events, while also commenting on Novartis' $3.5 billion acquisition deal with Chinook Therapeutics.
**↗️** [**Biogen (BIIB)**](https://www.wsj.com/market-data/quotes/BIIB): The biotech company's shares rose 1.3% after an advisory committee [recommended the Food and Drug Administration approve Leqembi](https://investors.
The latest investor updates on stocks that are trending on Monday.
Novartis to acquire Chinook for $40 per share in cash, with potential to receive up to an additional $4 per share in cash through contingent value rights, for a total equity value of up to approximately $3.5 billionChinook’s diversified pipeline of potentially best-in-class programs for rare, severe chronic kidney diseases will significantly expand the Novartis renal portfolio, complementing its existing pipelineTransaction expected to be completed in the second half of 2023, subject to customar
SEATTLE, May 16, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY) today announced it has entered a collaboration agreement with Ionis Pharmaceuticals, Inc. for the discovery, development and commercialization of an antisense oligonucleotide (ASO) therapy for a rare, severe chronic kidney disease with significant unmet medical need. The companies will leverage Chinook’s precision medicine approach and deep expertise in nephrology and Ionis’ extensive expertise in RNA-targeted th
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today reported financial results for the first quarter ended March 31, 2023 and provided corporate updates. “During the first quarter of 2023, we continued to advance our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We recently completed fu
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved new employment inducement grants of stock options to purchase a total of 88,000 shares of common stock and restricted stock units for 44,600 shares with a grant date of April 28, 2023 (the “